Dezheng Huo to Survival Analysis
This is a "connection" page, showing publications Dezheng Huo has written about Survival Analysis.
Connection Strength
0.913
-
Palliative Care Use Trends, Racial/Ethnic Disparities, and Overall Survival Differences Among Patients With Metastatic Breast Cancer. J Palliat Med. 2024 06; 27(6):763-775.
Score: 0.162
-
Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. Breast Cancer Res. 2021 02 04; 23(1):18.
Score: 0.132
-
Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy? Cancer. 2019 01 15; 125(2):213-222.
Score: 0.113
-
Follow-up of Patients with Clear-Cell Adenocarcinoma of the Vagina and Cervix. N Engl J Med. 2018 05 03; 378(18):1746-1748.
Score: 0.109
-
Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. JAMA Oncol. 2017 12 01; 3(12):1654-1662.
Score: 0.106
-
Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore). 2016 Oct; 95(40):e4975.
Score: 0.098
-
Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Med. 2019 09; 8(12):5609-5618.
Score: 0.030
-
Limited influence of germline genetic variation on all-cause mortality in women with early onset breast cancer: evidence from gene-based tests, single-marker regression, and whole-genome prediction. Breast Cancer Res Treat. 2017 Aug; 164(3):707-717.
Score: 0.025
-
The Thr300Ala variant in ATG16L1 is associated with improved survival in human colorectal cancer and enhanced production of type I interferon. Gut. 2016 Mar; 65(3):456-64.
Score: 0.022
-
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat. 2012 Jun; 133(3):865-80.
Score: 0.017
-
Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011 Aug; 128(3):703-711.
Score: 0.016
-
Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21.
Score: 0.015
-
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32.
Score: 0.013
-
Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007 Feb; 127(2):197-205.
Score: 0.012
-
Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6.
Score: 0.012
-
Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. Cancer Lett. 2005 Nov 08; 229(1):135-48.
Score: 0.011
-
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003 May 15; 21(10):1980-7.
Score: 0.010
-
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 01; 102(1):43-52.
Score: 0.010